+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients



Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients



Journal of Thoracic Oncology 4(7): 838-844



To assess for variables predicting pulmonary function test (PFT) changes after stereotactic body radiotherapy (SBRT) for medically inoperable stage I lung cancer. We reviewed 92 consecutive patients undergoing SBRT for stage I lung cancer between February 2004 and August 2007. A total of 102 lesions were treated using prescriptions of 20 Gy x 3 (n = 40), 10 Gy x 5 (n = 56), and 5 Gy x 10 (n = 6). Institutional practice was 10 Gy x 5 before March 1, 2006 before changing to 20 Gy x 3 to conform to RTOG 0236 unless otherwise dictated clinically. Median pretreatment forced expiratory volume at 1 second (FEV1) was 1.21 liter (50% of predicted) and median diffusion capacity to carbon monoxide (DLCO) was 56.5. There was no significant overall change in PFT's after SBRT. Individual patients experienced both substantial improvements and declines (10% declined at least 14% predicted FEV1% and 19% predicted DLCO). The mean change in FEV1 was -0.05 liter (range, -0.98 to +1.29 liter; p = 0.22) representing -1.88% predicted baseline FEV1 (range, -33 to + 43%; p = 0.62). DLCO declined 2.59% of predicted (range, -37 to +33%; p = 0.27). Conformality index, V5 and V10 were associated with individual patient changes in FEV1% (p = 0.033, p = 0.0036, p = 0.025, respectively), however, correlations were small and overall treatment dose did not predict for changes (p = 0.95). There was no significant difference in FEV1 (p = 0.55) or FEV1% (p = 0.37) changes for central versus peripheral locations. No factors predicted for individual changes in DLCO. Patients with FEV1% below the median of the study population had significantly longer overall survival (p = 0.0065). Although patients dying of cardiac disease died earlier than those dying of other causes, FEV1% below median was not associated with a lower risk of dying of cardiac disease or with lower Charlson comorbidity index. (1) SBRT was well tolerated and PFT changes were minimal. (2) Central lesions were safely treated with 50 Gy.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 052269864

Download citation: RISBibTeXText

PMID: 19487961

DOI: 10.1097/jto.0b013e3181a99ff6


Related references

Stereotactic body radiotherapy (SBRT) for medically inoperable lung metastases-A pooled analysis of the German working group "stereotactic radiotherapy". Lung Cancer 97: 51-58, 2017

Feasibility report of image guided stereotactic body radiotherapy (IG-SBRT) with tomotherapy for early stage medically inoperable lung cancer using extreme hypofractionation. Acta Oncologica 45(7): 890-896, 2006

A randomized Phase III trial of comparing two dose-fractionations stereotactic body radiotherapy (SBRT) for medically inoperable Stage IA non-small cell lung cancer or small lung lesions clinically diagnosed as primary lung cancer: Japan Clinical Oncology Group Study JCOG1408 (J-SBRT trial). Japanese Journal of Clinical Oncology 2017, 2017

A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer. Supportive Care in Cancer 21(1): 211-218, 2013

Stereotactic body radiotherapy (SBRT) for the treatment of inoperable stage I non-small cell lung cancer patients. Clinical and Translational Oncology 18(3): 259-268, 2016

Stereotactic body radiotherapy (SBRT) for lung cancer: Clinical experience for medically inoperable lung tumours with excellent local control. 2007

Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncologica 45(7): 787-795, 2006

(S010) Stereotactic Body Radiotherapy (Sbrt) for Operable vs. Medically Inoperable Stage I Non-Small Cell Lung Cancer: Long-Term Five-Year Outcomes and an Assessment by Fractionation Regimen, Tumor Size, and Tumor Location. International Journal of Radiation Oncology*Biology*Physics 98(2): E3-E4, 2017

Quality of life after stereotactic body radiotherapy (Sbrt) for early Nsclc in medically inoperable patients: preliminary analysis. Lung Cancer 75: S48-S49, 2012

Cost-effectiveness analysis of stereotactic body radiotherapy and radiofrequency ablation for medically inoperable, early-stage non-small cell lung cancer. International Journal of Radiation Oncology, Biology, Physics 81(5): E767-E774, 2012

Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I NonSmall Cell Lung Cancer Patients Treated With Stereotactic Body Radiotherapy. Yearbook of Pulmonary Disease 2010: 152-153, 2010

Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. Journal of Clinical Oncology 27(20): 3290-3296, 2009

Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). RadioTherapy and Oncology 107(3): 414-418, 2014

Intensity-modulated radiotherapy-based stereotactic body radiotherapy for medically inoperable early-stage lung cancer: excellent local control. International Journal of Radiation Oncology, Biology, Physics 77(2): 344-349, 2010

A Pilot Trial of Serial Ventilation and Perfusion Imaging in Patients with Medically Inoperable Stage I Non-small Cell Lung Cancer Treated with Stereotactic Body Radiotherapy. International Journal of Radiation Oncology*biology*physics 78(3): S511-S512, 2010